Enterprise Value
140M
Cash
140.6M
Avg Qtr Burn
-18.16M
Short % of Float
0.00%
Insider Ownership
0.00%
Institutional Own.
4.33%
Qtr Updated
12/31/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Elafibranor Details Primary biliary cholangitis, Liver disease Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
Nitazoxanide Details Acute-on-Chronic liver failure, Liver disease | Phase 2a Initiation | |
Elafibranor Details Non-alcoholic steatohepatitis | Failed Discontinued |